MECOM and leukemia: Treatment of murine Evi1-driven leukemias with the mTOR inhibitor rapamycin significantly prolonged the survival of recipient mice.54 This sensitivity towards inhibition of mTOR using rapamycin might also be an attractive therapeutic strategy for human EVI1high leukemia.